Cyclin A and Lung Cancer Survival
Author Information
Author(s): M Volm, R Koomagi, J Mattern, G Stammier
Primary Institution: German Cancer Research Centre
Hypothesis
Does cyclin A expression provide additional prognostic value for predicting survival and drug response in patients with non-small-cell lung carcinomas?
Conclusion
Patients with cyclin A-positive lung carcinomas had significantly shorter survival times compared to those with cyclin A-negative carcinomas.
Supporting Evidence
- 141 out of 187 NSCLCs showed expression of cyclin A.
- Patients with cyclin A-positive carcinomas had median survival times of 79 weeks.
- Patients with cyclin A-negative carcinomas had median survival times of 129 weeks.
- Expression of cyclin A correlated with response to doxorubicin in vitro.
Takeaway
This study found that if a lung cancer patient has cyclin A in their tumor, they might not live as long as someone whose tumor doesn't have cyclin A.
Methodology
Immunohistochemical analysis of formalin-fixed, paraffin-embedded tumor sections from patients with NSCLC.
Potential Biases
Potential bias in patient selection and tumor classification.
Limitations
The study may not account for all clinical parameters influencing survival.
Participant Demographics
187 patients (167 men, 20 women) aged 28 to 76 years, average age 58 years.
Statistical Information
P-Value
0.045
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website